WO2017209274A1 - アジュバント組成物とその利用 - Google Patents
アジュバント組成物とその利用 Download PDFInfo
- Publication number
- WO2017209274A1 WO2017209274A1 PCT/JP2017/020576 JP2017020576W WO2017209274A1 WO 2017209274 A1 WO2017209274 A1 WO 2017209274A1 JP 2017020576 W JP2017020576 W JP 2017020576W WO 2017209274 A1 WO2017209274 A1 WO 2017209274A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- granzyme
- antigen
- composition
- immunogenic substance
- protein
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims description 96
- 239000000427 antigen Substances 0.000 claims abstract description 106
- 102000036639 antigens Human genes 0.000 claims abstract description 106
- 108091007433 antigens Proteins 0.000 claims abstract description 106
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 40
- 102000001398 Granzyme Human genes 0.000 claims description 227
- 108060005986 Granzyme Proteins 0.000 claims description 224
- 210000004027 cell Anatomy 0.000 claims description 96
- 239000000126 substance Substances 0.000 claims description 76
- 230000002163 immunogen Effects 0.000 claims description 74
- 102000004169 proteins and genes Human genes 0.000 claims description 54
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 230000000694 effects Effects 0.000 claims description 52
- 150000001413 amino acids Chemical group 0.000 claims description 40
- 102000012479 Serine Proteases Human genes 0.000 claims description 38
- 108010022999 Serine Proteases Proteins 0.000 claims description 38
- 210000004443 dendritic cell Anatomy 0.000 claims description 36
- 230000005934 immune activation Effects 0.000 claims description 35
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 230000036039 immunity Effects 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 210000004989 spleen cell Anatomy 0.000 claims description 14
- 229960005486 vaccine Drugs 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 12
- 210000004102 animal cell Anatomy 0.000 claims description 11
- 102000037865 fusion proteins Human genes 0.000 claims description 11
- 108020001507 fusion proteins Proteins 0.000 claims description 11
- 230000004936 stimulating effect Effects 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- 230000007969 cellular immunity Effects 0.000 claims description 5
- 230000005847 immunogenicity Effects 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 abstract description 31
- 235000018102 proteins Nutrition 0.000 description 45
- 235000001014 amino acid Nutrition 0.000 description 30
- 241000699670 Mus sp. Species 0.000 description 18
- 230000006698 induction Effects 0.000 description 14
- 125000003275 alpha amino acid group Chemical group 0.000 description 13
- 108020004999 messenger RNA Proteins 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 239000002158 endotoxin Substances 0.000 description 11
- 230000001939 inductive effect Effects 0.000 description 11
- 229920006008 lipopolysaccharide Polymers 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- 230000035800 maturation Effects 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 9
- 208000035473 Communicable disease Diseases 0.000 description 7
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 7
- 230000004041 dendritic cell maturation Effects 0.000 description 7
- 210000005087 mononuclear cell Anatomy 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 229940022399 cancer vaccine Drugs 0.000 description 6
- 238000009566 cancer vaccine Methods 0.000 description 6
- 239000000411 inducer Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 102000008070 Interferon-gamma Human genes 0.000 description 5
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000000735 allogeneic effect Effects 0.000 description 5
- 229940037003 alum Drugs 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 229960003130 interferon gamma Drugs 0.000 description 5
- 241000282412 Homo Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 230000000240 adjuvant effect Effects 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- -1 erb-2 Proteins 0.000 description 4
- 239000003022 immunostimulating agent Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108050003624 Granzyme M Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101001009599 Homo sapiens Granzyme A Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 101100178679 Caenorhabditis elegans hsp-1 gene Proteins 0.000 description 1
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100035167 Coiled-coil domain-containing protein 54 Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000000805 Galectin 4 Human genes 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 description 1
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000737052 Homo sapiens Coiled-coil domain-containing protein 54 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000825253 Homo sapiens Sperm protein associated with the nucleus on the X chromosome A Proteins 0.000 description 1
- 101000824971 Homo sapiens Sperm surface protein Sp17 Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 108010010995 MART-1 Antigen Proteins 0.000 description 1
- 102100022430 Melanocyte protein PMEL Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101100337795 Micromonospora echinospora grm gene Proteins 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 102100023123 Mucin-16 Human genes 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 101000932479 Mus musculus Fms-related tyrosine kinase 3 ligand Proteins 0.000 description 1
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108010070641 PEC-60 polypeptide Proteins 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100040283 Peptidyl-prolyl cis-trans isomerase B Human genes 0.000 description 1
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 102100022327 Sperm protein associated with the nucleus on the X chromosome A Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 108010048032 cyclophilin B Proteins 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 108010044156 peptidyl-prolyl cis-trans isomerase b Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 108020002447 serine esterase Proteins 0.000 description 1
- 102000005428 serine esterase Human genes 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 101150047061 tag-72 gene Proteins 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 108010036927 trypsin-like serine protease Proteins 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21078—Granzyme A (3.4.21.78)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Definitions
- the present invention relates to an adjuvant capable of causing immunostimulation, particularly T cell immunization.
- the present invention relates to an adjuvant that can cause antigen-specific immunostimulation, in particular T cell immunization.
- Adjuvant is a term derived from “adjuvare”, which means Latin assistance, and refers to something that modifies the endogenous immunogenicity of an antigen in a vaccine.
- aluminum salts such as aluminum chloride, aluminum hydroxide and aluminum phosphate have been used as adjuvants
- incomplete Freund's adjuvant IFA
- IFA incomplete Freund's adjuvant
- Granzyme A is a protein having serine protease activity and was found in cytotoxic T lymphocytes (Non-patent Document 2). As a function of granzyme A, induction of apoptosis has been reported (Non-patent Document 3).
- the present invention provides an adjuvant capable of causing immune activation, particularly T cell immune activation.
- the present invention provides adjuvants that can cause antigen-specific immunostimulation, particularly T cell activation.
- the present invention provides an adjuvant capable of causing immune activation, particularly T cell immune activation.
- the present invention provides adjuvants that can cause antigen-specific immunostimulation, particularly T cell activation.
- the present inventors have revealed that granzyme A immunostimulates independently of serine protease activity.
- the present inventors have also clarified that antigen-specific immune activation occurs in this immune activation.
- the inventors further show that granzyme A induces antigen-specific T cell induction, dendritic cell maturation (eg, CD8 positive and / or CD8 negative dendritic cell maturation), production of interferon gamma. Also revealed that it causes.
- the present invention is based on such knowledge.
- An adjuvant composition comprising granzyme A or a protein having an amino acid sequence having 80% or more homology with granzyme A.
- Granzyme A in which serine protease activity is lower than that of the wild type is Granzyme A in which the amino acid corresponding to the 184th amino acid in the amino acid sequence shown in SEQ ID NO: 3 is substituted with serine to alanine
- Adjuvant composition Adjuvant composition.
- composition for antigen-specific immune activation according to the above (6) or (7), wherein the immunogenic substance is a polypeptide, and an effective amount of granzyme A or granzyme A as an adjuvant and 80
- a composition for antigen-specific immune activation comprising a protein having an amino acid homology of at least% in the form of a fusion protein with the immunogenic substance.
- a composition for use in stimulating immunity comprising granzyme A or a vector comprising a nucleic acid encoding a protein having 80% or more amino acid homology with granzyme A.
- a composition for use in stimulating immunity to the peptidic immunogenic substance which is contained in one vector or two or more vectors separately contained in the combination described in (12) above .
- An animal cell that is transformed with the composition according to (13) and expresses granzyme A and the immunogenic substance.
- a fusion protein comprising a peptide-like immunogenic substance and granzyme A or a protein having 80% or more amino acid homology with granzyme A, and having immunogenicity.
- a composition for antigen-specific immune activation comprising the cell according to (14) or (16) as an active ingredient.
- a composition for antigen-specific immune activation comprising the combination according to (18) above.
- Composition comprising a peptide-like immunogenic substance and granzyme A or a protein having 80% or more amino acid homology with granzyme A, and having immunogenicity.
- FIG. 1 is a diagram showing that cells expressing an antigen and granzyme A induce antigen-specific T cells.
- the antigen is ovalbumin.
- granzyme A is sometimes abbreviated as grmA, and the same applies to the following figures.
- FIG. 2 shows that antigen-specific T cell induction is caused more strongly by granzyme A than other granzymes (see FIG. 2A).
- FIG. 2 is also a diagram showing that granzyme A hardly induces serine protease activity of granzyme in antigen-specific T cell induction (see FIG. 2B).
- S184A gzmA in the figure is a mutant that substantially lost serine protease activity of granzyme A.
- FIG. 3 is a diagram showing that granzyme A has an action to mature dendritic cells equivalent to or stronger than lipopolysaccharide (hereinafter also referred to as “LPS”).
- DC means a dendritic cell.
- CD86 in the figure is a marker of mature dendritic cells.
- FIG. 4 shows that granzyme A matures CD8 positive dendritic cells and CD8 negative dendritic cells equal to or stronger than lipopolysaccharide (hereinafter also referred to as “LPS”).
- FIG. 5 shows that antigen-specific T cells are induced when an antigen and granzyme A are administered to mice (see FIG. 5A).
- FIG. 5A shows that antigen-specific T cells are induced when an antigen and granzyme A are administered to mice (see FIG. 5A).
- FIG. 5 is also a diagram showing that interferon ⁇ is produced when an antigen and granzyme A are administered to mice (see FIG. 5B).
- “Pep” in the figure means OVA.
- FIG. 6 shows that granzyme A can suppress cancer in an antigen-specific manner in mice.
- FIG. 7 shows that the production amount of antigen-specific IgG2 antibody increased in mice administered with antigen and granzyme A, and the production amount of antigen-specific IgG1 antibody in mice administered with antigen and aluminum hydroxide (Alum). It is a figure which shows that increases.
- adjuvant composition means a composition used as an adjuvant.
- an adjuvant composition may be referred to as an immunostimulant, an immunopotentiator, or a composition for use in immunostimulating.
- an adjuvant composition is used for inducing antigen-specific T cells, in particular for inducing antigen-specific CD8 single positive cells, so that dendritic cells (eg, CD8-positive trees) are used. For use in maturation of dendritic cells and CD8 negative dendritic cells).
- the CD8 single positive cell means a T cell that is positive for CD8 and negative for CD4, and includes, for example, cytotoxic T lymphocyte (CTL).
- CTL cytotoxic T lymphocyte
- immunogenic substance means a substance having immunogenicity in general.
- immunogenic substances substances that are exogenous antigens in the administration target (for example, toxoids such as bacterial toxoids, viruses, virus-like particles (VLPs), protein complexes, proteins, polypeptides, liposomes, and antigens are expressed.
- toxoids such as bacterial toxoids, viruses, virus-like particles (VLPs), protein complexes, proteins, polypeptides, liposomes, and antigens are expressed.
- the “peptidic immunogenic substance” means a peptide having a modification such as a post-translational modification or a peptide not having a modification such as a post-translational modification and having an immunogenicity. .
- nucleic acid means a biopolymer in which nucleotides are linked. Nucleic acids include deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).
- DNA deoxyribonucleic acid
- RNA ribonucleic acid
- animal means an animal with an immune system, particularly acquired immunity, and includes vertebrates, eg, birds or mammals, eg, mammals, eg, primates, especially humans. It is done.
- the term “animal” is used to include humans as described above, and is described as a non-human animal when humans are excluded.
- administered in combination with A and B or similar analogs, as long as A and B are administered in combination, A and B may be administered in combination, or A And B may be administered separately or simultaneously or sequentially.
- Gramzyme A is a serine protease produced by cytotoxic T lymphocytes (CTL) and natural killer cells (NK cells), and cytotoxic T lymphocyte-related serine esterase 3 (CTLA3). ), Also referred to as cytotoxic T lymphocyte and NK cell specific trypsin-like serine protease, or HANUKAH factor serine protease (HFSP).
- CTL cytotoxic T lymphocytes
- NK cells natural killer cells
- HFSP cytotoxic T lymphocyte-related serine esterase 3
- human granzyme A include a protein encoded by mRNA registered by NM_006144.3.
- the protein encoded by the mRNA registered by NM_006144.3 (having the amino acid sequence of SEQ ID NO: 2) is produced as a granzyme A precursor having a 26 amino acid signal peptide at the N-terminus. 254th is mature granzyme A.
- the amino acid sequence of mature human granzyme A can be, for example, SEQ ID NO: 3.
- an immunostimulatory agent or a composition for use in immunostimulation comprising granzyme A.
- Immunostimulation was antigen specific. Therefore, according to the present invention, there is provided an antigen-specific immunostimulating agent containing granzyme A or a composition for use in antigen-specific immunostimulation.
- the composition for use in immunostimulating agent or immunostimulation of the present invention can be administered to a subject in combination with an immunogenic substance as an antigen or a composition containing the same.
- the immunostimulatory promoter or composition for use in immunostimulation of the present invention is a composition administered to a subject in combination with an immunogenic substance as an antigen or a composition containing the same. It can be a thing.
- granzyme A induced antigen-specific T cells.
- granzyme A also induced antigen-specific T cells.
- granzyme A caused dendritic cell maturation.
- granzyme A matured both CD8-positive and CD8-negative dendritic cells.
- these antigen-specific T cell induction, antigen-specific CD8 single positive cell induction, dendritic cell maturation, CD8 positive dendritic cell maturation, and CD8 negative dendritic cell maturation are induced in vivo. It was.
- an antigen-specific T cell inducer comprising granzyme A, a composition for use in inducing antigen-specific T cells; antigen-specific CD8 comprising granzyme A A composition for use in inducing single positive cells; a composition for use in maturation of dendritic cells comprising granzyme A; a maturation of CD8 positive dendritic cells comprising granzyme A; and / or Alternatively, compositions for use in maturing CD8 negative dendritic cells can be provided, eg, they can be administered to a living body. Any of these inducers and compositions can be administered to a subject in combination with an immunogenic substance as an antigen or a composition containing the same.
- an antigen-specific T cell inducer comprising granzyme A as described above, a composition for use in inducing antigen-specific T cells; an antigen-specific T cell comprising granzyme A A composition for use in inducing cells; a composition for use in maturation of dendritic cells, comprising granzyme A; and maturation of CD8 positive dendritic cells comprising granzyme A; and / or A composition for use in maturing CD8 negative dendritic cells can be an inducer or composition administered to a subject in combination with an immunogenic substance as an antigen or a composition comprising the same.
- serine protease activity was not necessary for the adjuvant effect of granzyme A. Therefore, in one embodiment, instead of granzyme A, granzyme A in which serine protease activity is lower than that in the wild type, for example, granzyme A in which serine protease activity has been substantially lost, or granzyme A in which serine protease activity has been completely lost is used. Can be used. Examples of granzyme A having serine protease activity lower than that of the wild type include granzyme A in which serine corresponding to the 184th amino acid in the amino acid sequence of SEQ ID NO: 3 is substituted with another amino acid (for example, alanine), It can be used in the invention.
- granzyme A which is an active ingredient for the adjuvant effect, can be used in the form of a cell preparation supplied by cells expressing granzyme A or cells incorporating granzyme A.
- Cells expressing granzyme A or cells incorporating granzyme A may be either allogeneic or allogeneic. From the viewpoint that granzyme A can be supplied without being rejected in the body of the administration subject, Homogeneous and homologous are preferred.
- an immunostimulatory agent or a composition for use in immunostimulating comprising cells expressing granzyme A or cells incorporating granzyme A.
- an antigen-specific immunostimulator or a composition for use in antigen-specific immunostimulation comprising cells expressing granzyme A or cells incorporating granzyme A.
- an antigen-specific T cell inducer comprising a cell expressing granzyme A or a cell incorporating granzyme A, a composition for use in inducing an antigen-specific T cell A composition for use in inducing antigen-specific T cells, including cells expressing granzyme A or cells incorporating granzyme A; comprising cells expressing granzyme A or cells incorporating granzyme A; Compositions used to mature dendritic cells; mature CD8 positive dendritic cells and / or mature CD8 negative dendritic cells, including cells expressing granzyme A or cells incorporating granzyme A Compositions can be provided for use, eg, they can be administered to a living body.
- the immunogenic substance may be incorporated into the cells together with clanzyme A, or may be expressed in the cells. It may be.
- granzyme A can be administered to a subject in combination with an immunogenic substance as an antigen, a composition containing the same, or a cell having the composition.
- the immunostimulatory agent or composition for use in immunostimulation of the present invention is a composition administered to a subject in combination with an immunogenic substance as an antigen or a composition containing the same. obtain.
- the immunogenic substance can be administered separately with the cells.
- the immunogenic substance may be administered in a form that exists in the cell or on the cell membrane.
- an amino acid sequence having a sequence homology of 80% or more, preferably 85% or more, more preferably 90% or more, or even more preferably 95% or more with the amino acid sequence of SEQ ID NO: 3 instead of granzyme A.
- Protein for example, granzyme A having an amino acid sequence having a sequence homology of 80% or more, preferably 85% or more, more preferably 90% or more, or even more preferably 95% or more with the amino acid sequence of SEQ ID NO: 3. May be used).
- Sequence homology can be determined with default parameters, for example, by the FASTA program of Pearson and Lipman, PNAS, 85: 2444-2448, 1988.
- an immunogenic substance and an effective amount of granzyme A as an adjuvant or granzyme A having a serine protease activity decreased from that of the wild type or a protein having 80% or more amino acid homology with these are included.
- a composition for antigen-specific immune activation is provided. When the composition of the present invention is administered to a living body, immunity specific to an immunogenic substance can be activated.
- a conjugate of an immunogenic substance and granzyme A or granzyme A having serine protease activity lower than that of the wild type or a protein having 80% or more amino acid homology with these In the above conjugate, the immunogenic substance and granzyme A or granzyme A whose serine protease activity is lower than that of the wild type or a protein having 80% or more amino acid homology with these are bound via a linker. Also good.
- Such a conjugate is permissible as long as it does not inhibit the adjuvant ability of granzyme A, and can exert an effect as a composition for antigen-specific immune activation by interacting intramolecularly or intermolecularly.
- the antigen-specific immune activation composition of the present invention has an effective amount of granzyme A as an adjuvant or granzyme A having a serine protease activity decreased from that of the wild type or 80% or more amino acid homology with these.
- the protein having can be included in the form of a conjugate with an immunogenic substance.
- the immunogenic substance is conjugated to granzyme A or a protein having 80% or more amino acid homology with granzyme A or serine protease activity reduced from the wild type via a linker. May be.
- the immunogenic substance is a polypeptide, and an effective amount of granzyme A as an adjuvant or granzyme A having a serine protease activity reduced from that of the wild type or 80% or more amino acid homology with these. Proteins and fusion proteins with the immunogenic substances are provided.
- the immunogenic substance may be conjugated to granzyme A or a protein having 80% or more amino acid homology with granzyme A or serine protease activity reduced from the wild type via a linker. . As long as such a conjugate does not inhibit the adjuvant ability of granzyme A, it can interact intramolecularly or intermolecularly and exert an effect as a composition for antigen-specific immune activation.
- nucleic acid encoding the fusion protein of the present invention is provided.
- the immunogenic substance in the composition for antigen-specific immune activation of the present invention, is a polypeptide, and the effective amount of granzyme A or serine protease activity as an adjuvant is lower than that of the wild type.
- Granzyme A or a protein having 80% or more amino acid homology with these may be included in the form of a fusion protein with the immunogenic substance.
- the immunogenic substance is a polypeptide, there is an advantage in that it can be supplied as a fusion peptide with granzyme A. In this case, the fusion may be made via a peptidic linker.
- the immunogenic substance may be a membrane protein, in which case it is presented on the cell surface or VLP. Or in the state of being taken up into cells.
- the cells may have granzyme A and an immunogenic substance as a conjugate as described above, or have granzyme A and a peptidic immunogenic substance as a fusion protein as described above. It may be.
- “the cell has X” means that the cell may contain X or may be presented on the cell surface.
- the animal cell can be an autologous cell or a non-self cell for the administration subject, and the non-self cell can be, for example, an allogeneic animal cell.
- the kind of cell is not specifically limited, For example, it can be set as a somatic cell, a dendritic cell, a blood cell, a lymphocyte, a spleen cell, etc.
- Methods for expressing proteins such as granzyme in cells are well known to those skilled in the art.
- a method using a viral vector, a method using an expression plasmid vector, a method for introducing mRNA, and the like can be used.
- a method for incorporating a protein such as granzyme and an immunogenic substance into cells is well known to those skilled in the art and can be appropriately carried out by those skilled in the art.
- spleen cells are used as cells, and after incubating under high osmotic pressure conditions in the presence of an immunogenic substance, apoptosis is induced under low osmotic pressure conditions, whereby the immunogenic substance is converted into cells.
- the immunogenic substance can be a cancer antigen.
- all adjuvant compositions and antigen-specific immune activation compositions of the invention are vertebrates, eg, birds or mammals, eg, mammals, eg, primates, especially humans. Can be administered.
- the antigen-specific immune activation composition of the present invention may be used as a vaccine.
- the composition for antigen-specific immune activation of the present invention can be used as a vaccine such as a cancer vaccine and an infectious disease vaccine for the purpose of treatment or prevention.
- the composition for antigen-specific immune activation of the present invention is a subject in need thereof, for example, a subject suffering from cancer or an infectious disease, It is administered to the determined subject.
- the antigen-specific immune activation composition of the present invention is a subject suspected of suffering from cancer or an infectious disease or a subject determined to be suspected Administered to a subject in which it is desirable or desirable to prevent recurrence of cancer, or to a subject in which it is desirable or desirable to prevent the onset of infection. Therefore, according to the present invention, granzyme A or granzyme A having serine protease activity decreased from the wild type or 80 for use as vaccines such as cancer vaccines and infectious disease vaccines.
- a composition for antigen-specific immune activation comprising a protein having at least% amino acid homology.
- the immunogenic substance can be a cancer antigen, and the cancer antigen is included in the immunogenic composition in various forms such as a form presented to cells and a form presented to VLPs. Can be made.
- the immunogenic substance is preferably a vaccine used for the prevention of infectious diseases.
- a nucleic acid encoding granzyme A or granzyme A having a serine protease activity reduced from that of the wild type, or a protein having 80% or more amino acid homology with these, and a nucleic acid encoding a peptidic immunogenic substance are: They may be provided on the same vector or supplied on separate vectors. And when provided on the same vector, they may be linked in frame and via or without a linker so as to be expressed as a fusion protein.
- the nucleic acid can be incorporated into an expression vector so as to be operably linked to, for example, a promoter capable of driving expression in the cell and to allow expression of the protein from the nucleic acid in the cell.
- expression vectors such as these can also be provided.
- Nucleic acid encoding granzyme A or granzyme A in which serine protease activity is lower than that of the wild type or a protein having 80% or more amino acid homology with these and nucleic acid encoding peptidic immunogenic substance are expressed separately
- the present invention provides a combination of these expression vectors.
- nucleic acid that encodes granzyme A or granzyme A having a serine protease activity lower than that of the wild type or a protein having 80% or more amino acid homology with these a nucleic acid that encodes a peptidic immunogenic substance
- Animal cells containing one or more vectors into which the combinations are expressed are provided. These cells may be allogeneic or allogeneic in the subject to be administered.
- an animal cell comprising an antigenic peptide and granzyme A or granzyme A whose serine protease activity is lower than that of the wild type or a combination thereof with a protein having 80% or more amino acid homology.
- the present invention also provides an antigen-specific immunity comprising an animal cell comprising an antigenic peptide and granzyme A or a combination of granzyme A having a serine protease activity reduced from that of the wild type or a protein having 80% or more amino acid homology with these.
- An activation composition is provided.
- the immunogenic substance may be incorporated into cells and administered.
- granzyme A may be supplied into the same cell, may be supplied into another cell, or may be supplied in combination with a cell supplied as a peptide and incorporating an immunogenic substance.
- the present invention includes granzyme A or a protein having 80% or more amino acid homology with granzyme A or serine protease activity that is administered in combination with spleen cells that have taken up antigen peptide and has a reduced activity compared to wild type.
- a composition for use in stimulating immunity to the antigenic peptide is provided.
- a method for stimulating antigen-specific immunity in a subject, activating immunity by an antigen-specific T cell (eg, CD8SP cell) and / or maturating dendritic cells comprising granzyme A method comprising administering to a subject a combination of A or a serine protease activity-reduced granzyme A or a protein having 80% or more amino acid homology with these and an immunogenic substance as an antigen Is done.
- an antigen-specific T cell eg, CD8SP cell
- maturating dendritic cells comprising granzyme A method comprising administering to a subject a combination of A or a serine protease activity-reduced granzyme A or a protein having 80% or more amino acid homology with these and an immunogenic substance as an antigen Is done.
- the present invention provides the use of granzyme A in the manufacture of an immunostimulatory agent or a composition for use in immunostimulating.
- use of granzyme A in the manufacture of an antigen-specific immunostimulating agent or a composition for use in antigen-specific immunostimulation in the present invention, an antigen-specific T cell inducer, a composition for use in inducing an antigen-specific T cell, a composition for use in inducing an antigen-specific T cell, dendritic Compositions for use in cell maturation, use of granzyme A in the manufacture of a composition for use in maturing CD8 positive dendritic cells and / or maturing CD8 negative dendritic cells are provided.
- composition of the present invention may contain an excipient.
- the composition of the present invention can be administered, for example, by parenteral administration (for example, intraperitoneal administration, intravenous administration, subcutaneous administration, intratumoral administration, etc.). These can be prepared to be suitable for parenteral administration.
- parenteral administration for example, intraperitoneal administration, intravenous administration, subcutaneous administration, intratumoral administration, etc.
- composition of the present invention may contain an adjuvant other than granzyme A.
- adjuvants include, but are not limited to, aluminum hydroxide and Freund's adjuvant. Even when adjuvants other than granzyme A are included, the effects of antigen-specific T cell induction and / or dendritic cell maturation can be brought about by granzyme A.
- Proteins and peptides such as granzyme A and peptidic immunogenic substances can be prepared by methods well known to those skilled in the art.
- a protein such as granzyme A a protein synthesized in a cell by introducing a nucleic acid encoding a protein such as granzyme A into an insect cell, a mammalian cell or the like can be used.
- a method such as introducing mRNA encoding the protein into the cell or introducing a vector expressing the protein into the cell.
- Proteins such as granzyme A can also be synthesized, for example, using a cell-free protein synthesis system.
- An expression vector that can express a protein in a selected host cell can be used.
- the expression vector may be an episomal vector or a vector that is integrated into the host cell genome when introduced into the cell.
- vectors such as plasmids and viral vectors can be used.
- Such expression vectors can be designed and prepared by methods well known to those skilled in the art.
- the target protein to be expressed is usually operably linked to a promoter.
- the promoter a promoter capable of expressing a protein in a host cell can be appropriately used.
- Expression vectors can be introduced into cells by methods well known to those skilled in the art.
- Example 1 Induction of Antigen-Specific Immunity
- gzmA granzyme A
- OVA ovalbumin
- NIH3T3 cells were treated with mRNA encoding OVA (Accession number: NM_205152). ) And mRNA encoding Granzyme A (Accession number: NM — 006144.3) were introduced by electroporation and intravenously administered to the pathogen-free C57BL / 6 mice via the tail vein. Seven days after administration, the spleen was excised from the mouse, strained using a cell strainer, red blood cells were hemolyzed with ACK lysing buffer and washed to obtain spleen-derived mononuclear cells.
- OVA-tet Spleen-derived mononuclear cells and tetramer of OVA 257-264 peptide (OVA-tet; manufactured by MBL, product number: TS-5001-1C) and FITC-labeled anti-CD8 antibody (manufactured by Biolegend, manufacturing number: 100706 ). OVA-specific T cell responses were detected by flow cytometry. As a control, untreated NIH3T3 cells were used. The result was as shown in FIG.
- OVA-specific immune activity in particular CD8 positive cells, was induced.
- OVA mRNA alone was introduced into NIH3T3 cells and intravenously administered to the mouse tail vein as described above.
- the number of CD8-positive cells obtained from mice after 7 days was 1, and granzyme A, granzyme B (Accession number: NM_013542), granzyme K (Accession number: NM_008196) or granzyme M (Accession number: The number of CD8 positive cells when the mRNA of (NM_008504) was introduced was compared by relative value. The result was as shown in FIG.
- granzyme A is a serine protease
- this enzyme activity is necessary for the above-described immunostimulatory activity of granzyme A.
- a S184A mutant in which serine at position 184 in the amino acid sequence of granzyme A (amino acid sequence of SEQ ID NO: 3) was replaced with alanine was prepared, and this mRNA was introduced into NIH3T3 cells together with OVA mRNA in the above experimental system. Thus, OVA-specific T cell induction was confirmed. The result was as shown in FIG.
- granzyme A is considered to be expressed in NIH3T3 cells. Since granzyme A was not released from NIH3T3 cells, it was suggested that granzyme A exerts an adjuvant effect by being destroyed by immune cells in the mouse body and released as cell contents.
- Granzyme A protein was synthesized using an insect cell (sf9 cell) -baculovirus expression system according to the manufacturer's manual.
- Mouse bone marrow cells were obtained from the peripheral blood of C57BL / 6 mice free of pathogenic bacteria. Specifically, bone marrow cells were collected from mouse femur and tibia, and mouse FLT3L (Peprotech Co., Ltd. 250-31L) 200 ng / ml was added to induce dendritic cell culture.
- Synthesized granzyme A (concentration: 1000 ng / mL) was added to the culture system of culture-induced CD11-positive dendritic cells, and after 24 hours, the cells were collected and washed, and anti-CD86 antibody (BD) was obtained by flow cytometry. And product number: 553690) and Streptavidin-PE (product number: 12-4317-87, manufactured by ebioscience) was used to examine the maturation of dendritic cells based on CD86 expression intensity.
- LPS manufactured by Invivogen, product number: tlrl-eklps
- negative controls no granzyme A or LPS was added, and an isotype antibody was used in place of the anti-CD86 antibody. The result was as shown in FIG.
- mice were intravenously administered with 20 ⁇ g of synthesized granzyme A. Sixteen hours after the administration, the spleen was collected and subjected to enzyme treatment using collagenase D (Roche, product number: 11088882001) to obtain a sufficient amount of dendritic cells. Next, splenic dendritic cells were stained with anti-CD11c antibody (BD, product number 550261) and anti-CD8a antibody (Biolegend, product number: 100706) to obtain CD8-positive and CD8-negative dendritic cells. Divided into. For each, maturation was examined by CD86 expression intensity as described above. The result was as shown in FIG.
- Example 3 Induction of immunity with granzyme A in vivo
- cells expressing both granzyme A and antigen were administered to a living body.
- granzyme A was administered to the living body as a protein.
- mice were immunized with OVA antigen according to the method described in Fujii S. et al., Journal of Experimental Medicine, 198 (2): 267-279, 2003, and the presence or absence of antigen-specific T cells was examined. Specifically, spleen cells were collected from the ascites of C57BL / 6 mice free of pathogenic bacteria. The obtained splenocytes were incubated in hyperosmotic medium (Hyper0.5M sucrose, 10% wt / vol polyethylene glycol 1540, 10 mM Hepes containing RPMI) for 10 minutes at 37 ° C.
- hyperosmotic medium Hyper0.5M sucrose, 10% wt / vol polyethylene glycol 1540, 10 mM Hepes containing RPMI
- OVA antigen-incorporated splenocytes were prepared by incubating with a hypotonic solution (DDW plus RPMI medium) for 2 minutes to induce apoptosis and washing with PBS.
- the obtained OVA antigen-incorporated spleen cells were administered to mice together with 20 ⁇ g of granzyme A synthesized by a cell-free protein synthesis system, and the spleen was collected to obtain spleen-derived mononuclear cells.
- the obtained spleen mononuclear cells were reacted with a tetramer of OVA 257-264 peptide, and an OVA-specific T cell response was detected with a flow cytometer.
- As a positive control 20 ⁇ g LPS and OVA antigen-incorporated spleen cells were used, and as a negative control, a buffer alone was used. The results were as described in FIG.
- OVA-specific T cell induction was confirmed in the group administered with OVA antigen-incorporated spleen cells and granzyme A (FIG. 5A right).
- OVA-specific T cell induction was not confirmed (middle of FIG. 5A).
- the isolated mononuclear cells were cultured for 6 hours in the absence or presence of OVA peptide (concentration 1 ⁇ M), and the change in production of interferon ⁇ before and after the culture (T cell response) was examined. Interferon ⁇ was measured by intracellular staining. The result was as shown in FIG.
- Example 4 Use as a cancer vaccine
- granzyme A can be used as an adjuvant that can induce an antigen-specific immune response.
- the suppressive effect of cancer cells by the induced immune response was examined.
- OVA antigen-incorporated spleen cells were prepared. 2 ⁇ 10 7 OVA antigen-incorporated spleen cells were intravenously administered to mice together with 20 ⁇ g of granzyme A, and 7 days later, 1 ⁇ 10 5 MO4 cells were subcutaneously administered to increase the growth effect of MO4 cells in the body. confirmed.
- the MO4 cell is known as a mouse melanoma cell line B16 cell in which OVA is forcibly expressed.
- mice to which only MO4 cells were administered were used. The result was as shown in FIG.
- the tumor size increased rapidly in the control group that did not pre-administer OVA antigen-incorporated spleen cells and granzyme A, whereas the pre-administered group increased tumor size.
- the pre-administered group increased tumor size.
- granzyme A has a strong adjuvant effect and is promising as a cancer vaccine.
- Example 5 Analysis of immune response induced by granzyme A
- the immune response induced by granzyme A was analyzed in more detail.
- peripheral blood was collected from the mice.
- a large amount of IgG1 groove and an amount of IgG2 antibody in the collected peripheral blood were measured using conventional methods. The result was as shown in FIG.
- granzyme A is a biological protein, it is expected to reduce side effects.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
臨床では、アジュバントとして塩化アルミニウム、水酸化アルミニウムおよびリン酸アルミニウムなどのアルミニウム塩(alum)が利用され、癌ワクチンには不完全フロイントアジュバント(IFA)が使用されてきたが、これらの効果は抗原特異的な免疫賦活化を誘導する上で、未だ十分といえない。また、これらの作用機序は不明であり、かつ、副作用の問題点が指摘され始めている(非特許文献1)。
(1)グランザイムAまたはグランザイムAと80%以上の相同性を有するアミノ酸配列を有するタンパク質を含む、アジュバント組成物。
(2)グランザイムAが、セリンプロテアーゼ活性が野生型よりも低下したグランザイムAである、上記(1)記載のアジュバント組成物。
(3)セリンプロテアーゼ活性が野生型よりも低下したグランザイムAが、配列番号3に示されるアミノ酸配列の184番目のアミノ酸に対応するアミノ酸がセリンからアラニンに置換されたグランザイムAである、上記(2)に記載のアジュバント組成物。
(4)T細胞性免疫またはB細胞性免疫を賦活化することに用いるための、上記(1)~(3)のいずれかに記載のアジュバント組成物。
(5)樹状細胞を成熟化させることに用いるための、上記(1)~(4)のいずれかに記載のアジュバント組成物。
(6)アジュバントとしての有効量のグランザイムAまたはグランザイムAと80%以上のアミノ酸相同性を有するタンパク質と、免疫原性物質とを含む、抗原特異的免疫活性化用組成物。
(7)アジュバントとしての有効量のグランザイムAまたはグランザイムAと80%以上のアミノ酸相同性を有するタンパク質を、免疫原性物質とのコンジュゲートの形態で含む、上記(6)に記載の抗原特異的免疫活性化用組成物。
(8)上記(6)または(7)に記載の抗原特異的免疫活性化用組成物であって、免疫原性物質がポリペプチドであり、アジュバントとしての有効量のグランザイムAまたはグランザイムAと80%以上のアミノ酸相同性を有するタンパク質を、前記免疫原性物質との融合タンパク質の形態で含む、抗原特異的免疫活性化用組成物。
(9)免疫原性物質が、がん抗原である、上記(6)~(8)のいずれかに記載の抗原特異的免疫活性化用組成物。
(10)ワクチンとして用いるための、上記(6)~(9)のいずれかに記載の抗原特異的免疫活性化用組成物。
(11)グランザイムAまたはグランザイムAと80%以上のアミノ酸相同性を有するタンパク質をコードする核酸を含むベクターを含む、免疫を賦活化することに用いるための組成物。
(12)上記(11)で定義された核酸と、ペプチド性の免疫原性物質をコードする核酸との組合せであって、前記ペプチド性の免疫原性物質に対する免疫を賦活化することに用いるための組合せ。
(13)上記(12)に記載の組合せが、1つのベクターまたは別々に含む2つ以上のベクターに含まれる、前記ペプチド性の免疫原性物質に対する免疫を賦活化することに用いるための組成物。
(14)上記(13)に記載の組成物で形質転換され、グランザイムAと前記免疫原性物質とを発現する、動物細胞。
(15)ペプチド性の免疫原性物質とグランザイムAまたはグランザイムAと80%以上のアミノ酸相同性を有するタンパク質との融合タンパク質であって、免疫原性を有する融合タンパク質。
(16)上記(15)に記載の融合タンパク質を有する動物細胞。
(17)上記(14)または(16)に記載の細胞を有効成分として含む、抗原特異的免疫活性化用組成物。
(18)グランザイムAまたはグランザイムAと80%以上のアミノ酸相同性を有するタンパク質を含む動物細胞と免疫原性物質との組合せであって、前記免疫原性物質に対する免疫を賦活化することに用いるための組合せ。
(19)上記(18)に記載の組合せを含む、抗原特異的免疫活性化用組成物。
(20)免疫原性物質取込み脾臓細胞と組み合わせて投与される、前記免疫原性物質に対する免疫を賦活化することに用いるための上記(1)~(5)のいずれか一項に記載のアジュバント組成物。
従って、本発明によれば、本発明によれば、グランザイムAを発現する細胞またはグランザイムAを取り込んだ細胞を含む、免疫賦活化剤または免疫賦活化することに用いるための組成物が提供される。本発明によれば、グランザイムAを発現する細胞またはグランザイムAを取り込んだ細胞を含む、抗原特異的な免疫賦活化剤または抗原特異的な免疫賦活化することに用いるための組成物が提供される。
また、本発明によれば、グランザイムAを発現する細胞またはグランザイムAを取り込んだ細胞を含む、抗原特異的なT細胞の誘導剤、抗原特異的なT細胞の誘導することに用いるための組成物;グランザイムAを発現する細胞またはグランザイムAを取り込んだ細胞を含む、抗原特異的なT細胞の誘導することに用いるための組成物;グランザイムAを発現する細胞またはグランザイムAを取り込んだ細胞を含む、樹状細胞を成熟化させることに用いる組成物;グランザイムAを発現する細胞またはグランザイムAを取り込んだ細胞を含む、CD8陽性樹状細胞を成熟化させることおよび/またはCD8陰性樹状細胞を成熟化させることに用いるための組成物が提供され得、例えば、これらは生体に投与され得る。
また、この態様では、グランザイムAは、抗原としての免疫原性物質またはこれを含む組成物若しくはこれを有する細胞と組み合わせて対象に投与することができる。ある態様では、本発明の免疫賦活化剤または免疫賦活化することに用いるための組成物は、抗原としての免疫原性物質またはこれを含む組成物と組み合わせて対象に投与される組成物であり得る。投与の際、免疫原性物質は、前記細胞と一緒に、別々に投与することができる。免疫原性物質は、細胞内または細胞膜上に存在する形態で投与してもよい。
この態様において、動物細胞は、投与対象に対して自己細胞または非自己細胞とすることができ、非自己細胞としては、例えば、同種異系の動物細胞とすることができる。細胞の種類は、特に限定されないが例えば、体細胞、樹状細胞、血球細胞、リンパ球、脾臓細胞などとすることができる。
本実施例では、グランザイムA(以下、「gzmA」と略す)がオボアルブミン(以下、「OVA」という)に対する特異的免疫を引き起こすことを明らかにした。
)と、グランザイムAをコードするmRNA(Accession番号:NM_006144.3)をエレクトロポレーションで導入し、病原菌フリーのC57BL/6マウスに尾静脈より静脈内投与した。投与7日後のマウスから脾臓を摘出し、セルストレイナーを用いて漉し、ACK lysing bufferで赤血球を溶血して洗浄し、脾臓由来単核球を得た。得られた脾臓由来単核球とOVA257-264ペプチドのテトラマー(OVA-tet;MBL社製、製品番号:TS-5001-1C)およびFITC標識-抗CD8抗体(Biolegend社製、製造番号:100706)と反応させた。フローサイトメトリーでOVA特異的T細胞反応を検出した。対照としては、未処理NIH3T3細胞を用いた。結果は、図1に示される通りであった。
上記実施例では、グランザイムAが免疫賦活化を誘導することを明らかにした。本実施例では、骨髄由来樹状細胞(以下「DC」と略す)への成熟に対するグランザイムAの効果を調べた。
実施例1では、グランザイムAと抗原の両方を発現する細胞を生体に投与した。本実施例では、グランザイムAをタンパク質として生体に投与した。
上述の実施例により、グランザイムAが抗原特異的な免疫応答を誘導できる、アジュバントとして利用できることを明らかにした。本実施例では、誘導した免疫応答によるがん細胞の抑制効果を調べた。
本実施例では、グランザイムAにより誘導される免疫応答をより詳細に解析した。
Claims (20)
- グランザイムAまたはグランザイムAと80%以上の相同性を有するアミノ酸配列を有するタンパク質を含む、アジュバント組成物。
- グランザイムAが、セリンプロテアーゼ活性が野生型よりも低下したグランザイムAである、請求項1に記載のアジュバント組成物。
- セリンプロテアーゼ活性が野生型よりも低下したグランザイムAが、配列番号3に示されるアミノ酸配列の184番目のアミノ酸に対応するアミノ酸がセリンから他のアミノ酸に置換されたグランザイムAである、請求項1または2に記載のアジュバント組成物。
- T細胞性免疫またはB細胞性免疫を賦活化することに用いるための、請求項1~3のいずれか一項に記載のアジュバント組成物。
- 樹状細胞を成熟化させることに用いるための、請求項1~4のいずれか一項に記載のアジュバント組成物。
- アジュバントとしての有効量のグランザイムAまたはグランザイムAと80%以上のアミノ酸相同性を有するタンパク質と、免疫原性物質とを含む、抗原特異的免疫活性化用組成物。
- アジュバントとしての有効量のグランザイムAまたはグランザイムAと80%以上のアミノ酸相同性を有するタンパク質を、免疫原性物質とのコンジュゲートの形態で含む、請求項6に記載の抗原特異的免疫活性化用組成物。
- 請求項6または7に記載の抗原特異的免疫活性化用組成物であって、免疫原性物質がポリペプチドであり、アジュバントとしての有効量のグランザイムAまたはグランザイムAと80%以上のアミノ酸相同性を有するタンパク質を、前記免疫原性物質との融合タンパク質の形態で含む、抗原特異的免疫活性化用組成物。
- 免疫原性物質が、がん抗原である、請求項6~8のいずれか一項に記載の抗原特異的免疫活性化用組成物。
- ワクチンとして用いるための、請求項7~9のいずれか一項に記載の抗原特異的免疫活性化用組成物。
- グランザイムAまたはグランザイムAと80%以上のアミノ酸相同性を有するタンパク質をコードする核酸を含むベクターを含む、免疫を賦活化することに用いるための組成物。
- 請求項11で定義された核酸と、ペプチド性の免疫原性物質をコードする核酸との組合せであって、前記ペプチド性の免疫原性物質に対する免疫を賦活化することに用いるための組合せ。
- 請求項12に記載の組合せが、1つのベクターまたは別々に含む2つ以上のベクターに含まれる、前記ペプチド性の免疫原性物質に対する免疫を賦活化することに用いるための組成物。
- 請求項13に記載の組成物で形質転換され、グランザイムAと前記免疫原性物質とを発現する、動物細胞。
- ペプチド性の免疫原性物質とグランザイムAまたはグランザイムAと80%以上のアミノ酸相同性を有するタンパク質との融合タンパク質であって、免疫原性を有する融合タンパク質。
- 請求項15に記載の融合タンパク質を有する動物細胞。
- 請求項14または16に記載の細胞を有効成分として含む、抗原特異的免疫活性化用組成物。
- グランザイムAまたはグランザイムAと80%以上のアミノ酸相同性を有するタンパク質を含む動物細胞と免疫原性物質との組合せであって、前記免疫原性物質に対する免疫を賦活化することに用いるための組合せ。
- 請求項17に記載の組合せを含む、抗原特異的免疫活性化用組成物。
- 免疫原性物質取込み脾臓細胞と組み合わせて投与される、前記免疫原性物質に対する免疫を賦活化することに用いるための請求項1~5のいずれか一項に記載のアジュバント組成物。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/305,630 US11382973B2 (en) | 2016-06-02 | 2017-06-02 | Adjuvant composition and use thereof |
JP2018521012A JP7068702B2 (ja) | 2016-06-02 | 2017-06-02 | アジュバント組成物とその利用 |
EP17806824.3A EP3466444A4 (en) | 2016-06-02 | 2017-06-02 | ADJUVANT COMPOSITION AND USE THEREOF |
CA3023491A CA3023491A1 (en) | 2016-06-02 | 2017-06-02 | Adjuvant composition and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016111021 | 2016-06-02 | ||
JP2016-111021 | 2016-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017209274A1 true WO2017209274A1 (ja) | 2017-12-07 |
Family
ID=60477570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/020576 WO2017209274A1 (ja) | 2016-06-02 | 2017-06-02 | アジュバント組成物とその利用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11382973B2 (ja) |
EP (1) | EP3466444A4 (ja) |
JP (1) | JP7068702B2 (ja) |
CA (1) | CA3023491A1 (ja) |
WO (1) | WO2017209274A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11382973B2 (en) * | 2016-06-02 | 2022-07-12 | Riken | Adjuvant composition and use thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004535202A (ja) * | 2001-07-17 | 2004-11-25 | リサーチ ディベロップメント ファンデーション | アポトーシス促進性蛋白質を含む治療剤 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6232456B1 (en) * | 1997-10-06 | 2001-05-15 | Abbott Laboratories | Serine protease reagents and methods useful for detecting and treating diseases of the prostate |
US7235358B2 (en) * | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
KR20150033726A (ko) * | 2006-07-05 | 2015-04-01 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제 |
US10125359B2 (en) * | 2007-10-25 | 2018-11-13 | Revalesio Corporation | Compositions and methods for treating inflammation |
JP5609925B2 (ja) * | 2012-07-09 | 2014-10-22 | 日亜化学工業株式会社 | 発光装置 |
EP3456734B1 (en) * | 2012-10-04 | 2022-01-05 | Research Development Foundation | Serine protease molecules and therapies |
WO2017209274A1 (ja) * | 2016-06-02 | 2017-12-07 | 国立研究開発法人理化学研究所 | アジュバント組成物とその利用 |
-
2017
- 2017-06-02 WO PCT/JP2017/020576 patent/WO2017209274A1/ja active Application Filing
- 2017-06-02 EP EP17806824.3A patent/EP3466444A4/en active Pending
- 2017-06-02 CA CA3023491A patent/CA3023491A1/en active Pending
- 2017-06-02 US US16/305,630 patent/US11382973B2/en active Active
- 2017-06-02 JP JP2018521012A patent/JP7068702B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004535202A (ja) * | 2001-07-17 | 2004-11-25 | リサーチ ディベロップメント ファンデーション | アポトーシス促進性蛋白質を含む治療剤 |
Non-Patent Citations (12)
Title |
---|
ANDOH, T ET AL.: "Granzyme A and proteinase-activated receptor 2 are involved in the induction of itch associated responses to mosquito allergy in mice", ACTA DERM VENEREOL, vol. 91, 2011, pages 611 - 639, XP055599620 * |
BUKCZYNSKI, J ET AL.: "Costimulatory ligand 4-1BBL( CD 137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses", vol. 101, no. 5, 2004, pages 1291 - 1296, XP055125520 * |
FUJII S. ET AL., JOURNAL OF EXPERIMENTAL MEDICINE, vol. 198, no. 2, 2003, pages 267 - 279 |
GERSHENFELD ET AL., SCIENCE, vol. 232, no. 4752, 1996, pages 854 - 858 |
GHERARDI ET AL., BRAIN, vol. 124, 2001, pages 1821 - 1831 |
HAYES, M P ET AL.: "Induction of target cell DNA release by the cytotoxic T lymphocyte granule protease granzyme A", J EXP MED, vol. 170, no. 3, 1989, pages 933 - 946, XP000653476, DOI: doi:10.1084/jem.170.3.933 * |
IYODA ET AL., J. EXP. MED., vol. 195, no. 10, pages 1289 - 1302 |
MARTINA, J A ET AL.: "Imaging of lytic granule exocytosis in CD 8+ cytotoxic T lymphocytes reveals a modified form of full fusion", CELL IMMUNOL, vol. 271, no. 2, 2011, pages 267 - 279, XP028314554, DOI: doi:10.1016/j.cellimm.2011.07.004 * |
MARTINVALET ET AL., CELL, vol. 133, no. 4, 2008, pages 681 - 692 |
PEARSON; LIPMAN, PNAS, vol. 85, 1988, pages 2444 - 2448 |
POWELL, T J ET AL.: "Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine", PLOS ONE, vol. 8, no. 5, 2013, XP055599614 * |
See also references of EP3466444A4 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11382973B2 (en) * | 2016-06-02 | 2022-07-12 | Riken | Adjuvant composition and use thereof |
Also Published As
Publication number | Publication date |
---|---|
EP3466444A4 (en) | 2019-12-11 |
JP7068702B2 (ja) | 2022-05-17 |
CA3023491A1 (en) | 2017-12-07 |
US11382973B2 (en) | 2022-07-12 |
US20190328870A1 (en) | 2019-10-31 |
JPWO2017209274A1 (ja) | 2019-03-28 |
EP3466444A1 (en) | 2019-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200165302A1 (en) | Modified vsv-g and vaccines thereof | |
US7446185B2 (en) | Her2/neu target antigen and use of same to stimulate an immune response | |
CN109069605B (zh) | 新免疫原性CD1d结合肽 | |
US11077177B2 (en) | Universal cancer vaccine | |
JP2018537999A (ja) | 樹状細胞組成物 | |
WO2009036568A1 (en) | Methods and compositions for treating tumors and viral infections | |
CN109810946B (zh) | 天花粉蛋白用于致敏和/激活树突状细胞中的应用 | |
US20220331417A1 (en) | Modified vesicular stomatitis virus glycoprotein and uses thereof for the treatment of brain tumors | |
JP2024036364A (ja) | I型インターフェロン遺伝子を刺激するための方法及びカチオン性脂質を含む組成物 | |
JP2017509652A (ja) | 細胞性の細胞傷害性免疫応答を誘導または延長する方法における使用のための医薬 | |
Kramer et al. | Functionalisation of Virus‐Like Particles Enhances Antitumour Immune Responses | |
WO2024164637A1 (zh) | 利用天然蛋白tsh作为抗原结合位点构建靶向tshr的car-t细胞 | |
WO2017209274A1 (ja) | アジュバント組成物とその利用 | |
KR20040104464A (ko) | 종양을 치료하기 위해 사용되는 세포 항원을 코딩하는뉴클레오티드 서열의 캐리어로서 기능하는 미생물 | |
CN110167576A (zh) | 靶向成纤维细胞活化蛋白的优化的合成共有免疫原性组合物 | |
EP2608802B1 (en) | Immunotherapeutic method for treating prostate cancer | |
JP4459060B2 (ja) | ポリヌクレオチドからなるワクチン | |
KR20190082195A (ko) | 난포 자극 호르몬 수용체 (fshr)를 표적으로 하는 최적화된 합성 콘센수스 면역원 조성물 | |
US6514493B1 (en) | cDNA clone for tumor rejection antigen gp110 and tumor peptide vaccine | |
CA3220605A1 (en) | Methods of treating or preventing autoimmune diseases | |
CN118667854A (zh) | 一种IFN-γ重组修饰的细菌囊泡及其制备方法和应用 | |
CN118005805A (zh) | 基于铁蛋白合理设计的具有抗原、siRNA共递送的可增强机体免疫的纳米疫苗 | |
Moran | Characterization of dendritic cells transduced with Venezuelan equine encephalitis virus replicon particles as therapeutic cancer vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2018521012 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 3023491 Country of ref document: CA |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17806824 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017806824 Country of ref document: EP Effective date: 20190102 |